My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

6.495 +0.325 (+5.27%)

Delayed Quote Updated: 1:09 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances ↗

May 27, 2026

Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal...

Via MarketBeat

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data ↗

May 19, 2026

Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the...

Via MarketBeat

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 09, 2026

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading...

Via Benzinga

Topics Stocks

Recap: Aura Biosciences Q4 Earnings ↗

March 27, 2024

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 06, 2026

Via Chartmill

Aura Biosciences Posts Q2 Cash Surge ↗

August 13, 2025

Via The Motley Fool

Topics Intellectual Property

4 Artificial Intelligence Stocks (That Aren't Nvidia) You Can Buy and Hold for the Next Decade ↗

July 29, 2025

These AI companies offer long-term growth potential and are worth holding for years to come.

Via The Motley Fool

Topics Artificial Intelligence

Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗

April 16, 2025

Via Benzinga

US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert ↗

March 27, 2025

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming...

Via Benzinga

Topics Supply Chain World Trade

Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket ↗

March 27, 2025

Via Benzinga

Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket ↗

January 03, 2025

Via Benzinga

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease ↗

October 18, 2024

Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 17, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 14, 2024

Via Benzinga

3 Small-Cap Stocks Ready to Deliver Significant Growth

October 10, 2024

Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.

Via MarketBeat

Topics Economy

Aura Biosciences Touts Promising Data From Eye Cancer Candidate ↗

September 12, 2024

Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control.

Via Benzinga

AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024 ↗

August 08, 2024

AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 ↗

May 09, 2024

AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 ↗

March 27, 2024

AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

March 27, 2024

From Aura Biosciences, Inc.

Via Business Wire

Aura Biosciences to Participate in Upcoming Investor Conferences

February 26, 2024

From Aura Biosciences Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 09, 2024

Via Benzinga

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

December 07, 2023

From Aura Biosciences Inc.

Via Business Wire

Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying ↗

November 10, 2023

Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

November 09, 2023

From Aura Biosciences, Inc.

Via Business Wire

Aura Biosciences to Participate in Upcoming Investor Conferences

November 08, 2023

From Aura Biosciences Inc.

Via Business Wire

Why Aura Biosciences Stock Hit A New 52-Week Low Today ↗

November 07, 2023

Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 07, 2023

Via Benzinga

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 07, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Via Benzinga

Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗

November 07, 2023

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.